History

Our HistoryPH PHARMA

COR  Corporate  201  PHP-201  303  PHP-303  TOR  Torpedo 
COR  Corporate
201  PHP-201
303  PHP-303
TOR  Torpedo
2021

303 Jan Awarded US-DoD grant for COVID-19 Treatment

2021
2020

303 Jan IND approved for Ph. II AATD study (GB, IE)

2020
2019

TOR Dec Signed an ADC co-development contract with Venn DC

TOR Oct Signed an ADC co-development contract with Immunome

303 Jul Completed Phase Ib MAD study in (US)

303 Jul Awarded Foundation grant for PHP-303 Alpha-1 research

COR May Asia Research Center opened in Pangyo (KR)

201 Mar PHP-201 Phase IIb results presented at APAO

303 Jan PHP-303 Phase Ib (MAD) initiated (US)

2019
2018

303 Dec PHP-303 Phase Ib (SAD) initiated (US)

201 Dec Completed Phase IIb clinical study report (CSR)

TOR Sep Patented an additional in-house novel toxin

303 Aug PHP-303 Phase Ib initiated (US)

201 Jun Completed Phase IIb study (KR)

COR Apr Global Research Center opened in Silicon Valley (US)

COR Mar Signed an investment contract with Pliant Therapeutics

TOR Feb Two toxins in-licensed from Purdue University

2018
2017

TOR Oct Patented our first in-house novel toxin

201 Feb PHP-201 Phase IIb study initiated (KR)

303 Feb PHP-303 acquired from Bayer

2017
2016

TOR Nov Initiated ADC toxin research program (Torpedo)

201 Oct IND is approved for Phase IIb study (KR)

COR Feb pH Pharma Inc. is established in Silicon Valley (US)

201 Feb PHP-201 in-licensed from Amakem Therapeutics

2016
2015

COR Sep pH Pharma Co., Ltd. established

2015